Q-omics provides the consensus-scored PPP6R2 profile across patient tissues and cancer cell-line models. PPP6R2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPP6R2 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, PPP6R2 protein abundance shows 23,370 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRP, and GBM as cancer lineages where PPP6R2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP6R2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP6R2 survival associations across molecular data types. PPP6R2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP6R2 RNA expression–survival associations across cancer types. High PPP6R2 expression shows unfavorable associations in ACC, UVM and OV, but favorable associations in ESCA, HNSC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPP6R2 RNA expression.
This table summarizes PPP6R2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP6R2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP6R2 shows lower tumor expression in KIRP, THCA and BRCA and higher tumor expression in LIHC, COAD and STAD. The KIRP box plot shows higher PPP6R2 RNA expression in normal versus tumor tissue (log2 FC = −0.686, t-test p < 0.001).
This table shows molecular features associated with PPP6R2 in patient tissues and cancer cell lines. In patient samples, PPP6R2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP6R2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
